Cipla receives final approval for generic Baraclude® tablets

Cipla completes acquisition of generic businesses in US

Cipla announces Q3 FY1516 Unaudited Consolidated Financial Results

Big Pharma’s Worst Nightmare

CARE reaffirms ‘CARE AAA / A1+’ rating

Global pharmaceutical industry calls on governments to work with them to beat the rising threat of drug resistance

CARE reaffirms ‘CARE AAA / A1+’ rating

The Medicines Patent Pool Signs First Sub-licences for Hepatitis C Medicine Daclatasvir

Cipla Announces its Management Council

BioQ Pharma and Cipla Enter into an Agreement to Commercialize BioQ’s Ropivacaine Infusion System in India